Facebook Instagram Linkedin Youtube
Home Tags ELC-100

Tag: ELC-100

Elicera’s CEO: “TO2 is a highly attractive opportunity to increase ownership...

Elicera’s CEO: ”2025 is a crucial year for us”

Elicera ODD

Elicera’s candidate ELC-100 granted Orphan Drug Designation

Elicera ELC-100

Elicera’s CEO: “ELC-100 stands apart from all other standard treatments”

Full speed ahead for Elicera in 2024

Full speed ahead for Elicera in 2024

Elicera's CEO: " iTANK has great potential in treating solid tumours"

Elicera’s CEO: ” iTANK has great potential in treating solid tumours”

Elicera uppdaterar i samband med Cancer Immunotherapy Month

Elicera gives an update in Cancer Immunotherapy Month

Elicera Q1 2023

Well-financed Elicera prepared for clinic and business development

Elicera Q4 2022

Advancements for Elicera in 2022 open for intensive clinical year

Elicera fas I signaler

Elicera on the positive clinical effect in cancer trial

12Page 1 of 2
© BioStock 2025